Journal article
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage
Abstract
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients from the ANNEXA-4 study (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors) with intracranial hemorrhage (ICrH).
Methods: ANNEXA-4 was a single-arm study evaluating andexanet in …
Authors
Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; MillingJr TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P
Journal
Stroke, Vol. 52, No. 6, pp. 2096–2105
Publisher
Wolters Kluwer
Publication Date
June 2021
DOI
10.1161/strokeaha.120.030565
ISSN
0039-2499